Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea
Latest Information Update: 08 May 2025
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms ONSET
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 30 Apr 2025 Status changed from not yet recruiting to recruiting.
- 08 Apr 2025 New trial record